Citations

Clear

3942 citation(s) found for "To, Van".

Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group
Hurley, Robert W. , Adams, Meredith C B , Barad, Meredith , Bhaskar, Arun , Bhatia, Anuj , Deer, Timothy R. , Hah, Jennifer M. , Hooten, W. Michael , Lee, David Wonhee, McCormick, Zachary L. , Schneider, Byron J. , Eerd, Maarten van , Zundert, Jan Van , Wallace, Mark S. , Wilson, Sara M, Zhao, Zirong , Chadwick, Andrea , Deer, Tim , Hooten, W Michael , Moon, Jee Youn , Narouze, Samer , Cohen, Steven P , van Zundert, Jan , Hurley, Robert W , Barad, Meredith J , Hah, Jennifer M , Bhatia, Anuj , Kissoon, Narayan , Narouze, Samer , Provenzano, David , Cohen, Steven P.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 11, 2021 | Volume: 47 | Issue: 1 | Pages: 3-59

10.1136/rapm-2021-103031 | PMID 34764220 Get It

Background The past two decades have witnessed a surge in the use of cervical spine joint procedures including joint injections, nerve blocks and radiofrequency ablation to treat chronic neck pain, yet many aspects of the procedures remain controversial. Methods In August 2020, the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine approved and charged the Cervical Joint Working Group to develop neck pain guidelines. Eighteen stakeholder societies were identified, and formal request-for-participation and member nomination letters were sent to those organizations. Participating entities selected panel members and an ad hoc steering committee selected preliminary questions, which were then revised by the full committee. Each question was assigned to a module composed of 4–5 members, who worked with the Subcommittee Lead and the Committee Chairs on preliminary versions, which were sent to the full committee after revisions. We used a modified Delphi method whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was reached. Before commencing, it was agreed that a recommendation would be noted with >50% agreement among committee members, but a consensus recommendation would require ≥75% agreement. Results Twenty questions were selected, with 100% consensus achieved in committee on 17 topics. Among participating organizations, 14 of 15 that voted approved or supported the guidelines en bloc, with 14 questions being approved with no dissensions or abstentions. Specific questions addressed included the value of clinical presentation and imaging in selecting patients for procedures, whether conservative treatment should be used before injections, whether imaging is necessary for blocks, diagnostic and prognostic value of medial branch blocks and intra-articular joint injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for designating a block as positive, how many blocks should be performed before radiofrequency ablation, the orientation of electrodes, whether larger lesions translate into higher success rates, whether stimulation should be used before radiofrequency ablation, how best to mitigate complication risks, if different standards should be applied to clinical practice and trials, and the indications for repeating radiofrequency ablation. Conclusions Cervical medial branch radiofrequency ablation may provide benefit to well-selected individuals, with medial branch blocks being more predictive than intra-articular injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of false-negatives (ie, lower overall success rate). Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.
Predicting pituitary adenoma consistency with preoperative magnetic resonance elastography
Cohen-Cohen, Salomón , Helal, Ahmed , Yin, Ziying , Ball, Matthew K. , Yin, Ziying , Ehman, Richard L. , Gompel, Jamie J. Van , Huston, John

Mayo Clinic

Journal of Neurosurgery | November 5, 2021 | Volume: 136 | Issue: 5 | Pages: 1356-1363

10.3171/2021.6.jns204425 | PMID 34715659 Get It

OBJECTIVE Pituitary adenoma is one of the most common primary intracranial neoplasms. Most of these tumors are soft, but up to 17% may have a firmer consistency. Therefore, knowing the tumor consistency in the preoperative setting could be helpful. Multiple imaging methods have been proposed to predict tumor consistency, but the results are controversial. This study aimed to evaluate the efficacy of MR elastography (MRE) in predicting tumor consistency and its potential use in a series of patients with pituitary adenomas. METHODS Thirty-eight patients with pituitary adenomas (≥ 2.5 cm) were prospectively evaluated with MRI and MRE before surgery. Absolute MRE stiffness values and relative MRE stiffness ratios, as well as the relative ratio of T1 signal, T2 signal, and diffusion-weighted imaging apparent diffusion coefficient (ADC) values were determined prospectively by calculating the ratio of those values in the tumor to adjacent left temporal white matter. Tumors were classified into three groups according to surgical consistency (soft, intermediate, and firm). Statistical analysis was used to identify the predictive value of the different radiological parameters in determining pituitary adenoma consistency. RESULTS The authors included 32 (84.21%) nonfunctional and 6 (15.79%) functional adenomas. The mean maximum tumor diameter was 3.7 cm, and the mean preoperative tumor volume was 16.4 cm 3 . Cavernous sinus invasion was present in 20 patients (52.63%). A gross-total resection was possible in 9 (23.68%) patients. The entire cohort’s mean absolute tumor stiffness value was 1.8 kPa (range 1.1–3.7 kPa), whereas the mean tumor stiffness ratio was 0.66 (range 0.37–1.6). Intraoperative tumor consistency was significantly correlated with absolute and relative tumor stiffness (p = 0.0087 and 0.007, respectively). Tumor consistency alone was not a significant factor for predicting gross-total resection. Patients with intermediate and firm tumors had more complications compared to patients with soft tumors (50.00% vs 12.50%, p = 0.02) and also had longer operative times (p = 0.0002). CONCLUSIONS Whereas other MRI sequences have proven to be unreliable in determining tumor consistency, MRE has been shown to be a reliable tool for predicting adenoma consistency. Preoperative knowledge of tumor consistency could be potentially useful for surgical planning, counseling about potential surgical risks, and estimating the length of operative time.
Management recommendations for pancreatic manifestations of von Hippel–Lindau disease
Leeuwaarde, Rachel van, Keutgen, Xavier M. , Nilubol, Naris , Links, Thera P. , Daniels, Anthony B. , Tirosh, Amit , Laks, Shachar , Patel, Dhaval , Hammel, Pascal , Hálfdánarson, Þorvarður R.

Mayo Clinic

Cancer | November 4, 2021 | Volume: 128 | Issue: 3 | Pages: 435-446

10.1002/cncr.33978 | PMID 34735022 Get It

Von Hippel–Lindau disease (VHL) is a multineoplasm inherited disease manifesting with hemangioblastoma of the central nervous system and retina, adrenal pheochromocytoma, renal cell carcinoma, pancreatic neuroendocrine tumors and cysts, and neoplasms/cysts of the ear, broad ligament, and testicles. During 2018‐2020, the VHL Alliance gathered several committees of experts in the various clinical manifestations of VHL to review the literature, gather the available evidence on VHL, and develop recommendations for patient management. The current report details the results of the discussion of a group of experts in the pancreatic manifestations of VHL along with their proposed recommendations for the clinical surveillance and management of patients with VHL. The recommendations subcommittee performed a comprehensive systematic review of the literature and conducted panel discussions to reach the current recommendations. The level of evidence was defined according to the Shekelle variation of the Grading of Recommendations, Assessment, Development, and Evaluation grading system. The National Comprehensive Cancer Network Categories of Evidence and Consensus defined the committee members' interpretation of the evidence and degree of consensus. The recommendations encompass the main aspects of VHL‐related pancreatic manifestations and their clinical management. They are presented in a clinical orientation, including general planning of screening and surveillance for pancreatic neuroendocrine tumors, utility of biochemical biomarkers, the optimal choice for imaging modality, indirect risk stratification, indications for tissue sampling of VHL‐related pancreatic neuroendocrine tumors, and interventions. These recommendations are designed to serve as the reference for all aspects of the screening, surveillance, and management of VHL‐related pancreatic manifestations.
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Kemps, Paul G. , Picarsic, Jennifer , Durham, Benjamin H. , Hélias‐Rodzewicz, Zofia , Hiemcke‐Jiwa, Laura S. , Bos, Cor van den , Noesel, Carel J.M. van , Laar, Jan van , Verdijk, Robert M. , Flucke, Uta , Hogendoorn, Pancras C.W. , Woei-A-Jin, Feng Jung Sherida H. , Beilken, Andreas , Ebinger, Martin , Möhle, Robert, Bornemann, Antje, Wiegering, Verena , Ernestus, Karen, Méry, Tina, Gryniewicz–Kwiatkowska, Olga , Evseev, D. A. , Gaspari, Stefania , Gessi, Marco , Tamburrini, Gianpiero , Héritier, Sébastien , Bonneau‐Lagacherie, Jacinthe, Lamaison, Claire, Farnault, Laure , Fraitag, Sylvie , Jullié, Marie‐Laure , Haroche, Julien , Allotey, Jackie, Madni, Majid, Turner, Kerry , Picton, Susan, Barbaro, Pasquale , Poulin, Alysa, Tam, Ingrid S. , Empringham, Brianna , Whitlock, James A. , Swanson, Amy A. , Suchi, Mariko, Brandt, Jon M., Yaseen, Nabeel R. , Weinstein, Joanna , Eldem, İrem , Sisk, Bryan A. , Sridhar, Vaishnavi , Atkinson, Mandy, Massoth, Lucas R. , Alexandrescu, Sanda , Yeo, Kee Kiat , Petrova‐Drus, Kseniya , Peeke, Stephen , Muñoz-Arcos, Laura , Leino, Daniel , Grier, David D. , Lorsbach, Robert B., Kumar, Ashish R. , Garg, Shipra , Tiwari, Nishant , Schafernak, Kristian T. , Henry, M M , Halteren, Astrid G. S. van , Abla, Oussama , Kumar, Ashish , Hiemcke-Jiwa, Laura , van den Bos, Cor , van Noesel, Carel J M , van Laar, Jan A M , Verdijk, Robert M , Flucke, Uta E , Hogendoorn, Pancras C W , Woei-A-Jin, F J Sherida H , Sciot, Raf , Beilken, Andreas , Feuerhake, Friedrich , Ebinger, Martin , Fend, Falko , Wiegering, Verena , Gryniewicz-Kwiatkowska, Olga , Dembowska-Baginska, Bozenna , Evseev, Dmitry A , Potapenko, Vsevolod , Baykov, Vadim V , Gaspari, Stefania , Rossi, Sabrina , Gessi, Marco , Tamburrini, Gianpiero , Héritier, Sébastien , Donadieu, Jean , Farnault, Laure , Fraitag, Sylvie , Jullié, Marie-Laure , Collin, Matthew , Turner, Kerry , Barbaro, Pasquale M , Tam, Ingrid S , El Demellawy, Dina , Empringham, Brianna , Raghunathan, Aditya , Suchi, Mariko , Weinstein, Joanna L , Eldem, Irem , Sisk, Bryan A , Massoth, Lucas R , Hornick, Jason L , Alexandrescu, Sanda , Yeo, Kee Kiat , Petrova-Drus, Kseniya , Peeke, Stephen Z , Muñoz-Arcos, Laura S , Leino, Daniel G , Grier, David D , Roy, Somak , Kumar, Ashish R , Henry, Michael M , van Halteren, Astrid G S , Abla, Oussama , Diamond, Eli L , Emile, Jean-François , Picarsic, Jennifer L , Schafernak, Kristian , Durham, Benjamin , Wetering, Marianne D. van de , Sciot, Raf , Rossi, Sabrina , Collin, Matthew , Raghunathan, Aditya , Hornick, Jason L. , Diamond, Eli L. , Emile, Jean‐François

Mayo Clinic

Blood | November 2, 2021 | Volume: 139 | Issue: 2 | Pages: 256-280

10.1182/blood.2021013338 | PMID 34727172 Get It

Abstract ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.
What factors drive polyethylene wear in total knee arthroplasty?
Currier, Barbara H. , Berry, Daniel J. , Titus, Alexander , Currier, Barbara H , Berry, Daniel J , Currier, John H. , Abdel, Matthew P. , Citters, Douglas W. Van

Mayo Clinic

The Bone & Joint Journal | November 1, 2021 | Volume: 103-B | Issue: 11 | Pages: 1695-1701

10.1302/0301-620x.103b11.bjj-2020-2334.r1 | PMID 34719265 Get It

Aims Wear of the polyethylene (PE) tibial insert of total knee arthroplasty (TKA) increases the risk of revision surgery with a significant cost burden on the healthcare system. This study quantifies wear performance of tibial inserts in a large and diverse series of retrieved TKAs to evaluate the effect of factors related to the patient, knee design, and bearing material on tibial insert wear performance. Methods An institutional review board-approved retrieval archive was surveyed for modular PE tibial inserts over a range of in vivo duration (mean 58 months (0 to 290)). Five knee designs, totalling 1,585 devices, were studied. Insert wear was estimated from measured thickness change using a previously published method. Linear regression statistical analyses were used to test association of 12 patient and implant design variables with calculated wear rate. Results Five patient-specific variables and seven implant-specific variables were evaluated for significant association with lower insert wear rate. Six were significant when controlling for other factors: greater patient age, female sex, shorter duration in vivo, polished tray, highly cross-linked PE (HXLPE), and constrained knee design. Conclusion This study confirmed that knee wear rate increased with duration in vivo. Older patients and females had significantly lower wear rates. Polished modular tibial tray surfaces, HXLPE, and constrained TKA designs were device design factors associated with significantly reduced wear rate. Cite this article: Bone Joint J 2021;103-B(11):1695–1701.
p21 produces a bioactive secretome that places stressed cells under immunosurveillance
Sturmlechner, Ines , Sine, Chance , Deursen, Erik-Jan van, Jeganathan, Karthik B. , Hamada, Naomi, Grašič, Jan , Friedman, David J. , Stutchman, Jeremy, Can, İsmail , Hamada, Masakazu , Lim, Do Young , Lee, Jeong‐Heon , Ördög, Tamás , Laberge, Rémi-Martin , Baker, Darren J. , Deursen, Jan M. van , Sine, Chance C, van Deursen, Erik-Jan, Jeganathan, Karthik B , Friedman, David , Stutchman, Jeremy T, Can, Ismail , Lim, Do Young , Lee, Jeong-Heon , Ordog, Tamas , Shapiro, Virginia S , Baker, Darren J , Li, Hu , van Deursen, Jan M , Sturmlechner, Ines , Zhang, Cheng , Hamada, Masakazu, Shapiro, Virginia Smith

Mayo Clinic

Science | October 28, 2021 | Volume: 374 | Issue: 6567 | Pages: No page available

10.1126/science.abb3420 | PMID 34709885 Get It

The clock is ticking for senescent cells Senescent cells promote their own recognition and removal through the immune system by generating a bioactive secretome called the senescence-associated secretory phenotype (SASP). Sturmlechner et al . report that the cell cycle regulator p21 directs an early form of the SASP, which they call the p21-activated secretory phenotype (PASP) (see the Perspective by Reen and Gil). As part of the PASP, the chemokine CXCL14 attracts macrophages, which monitor stressed cells expressing elevated p21. If stressed cells recuperate and p21 levels return to normal within 4 days, then macrophages disengage from their targets. Otherwise, macrophages recruit cytotoxic T cells that facilitate target cell removal. Other cell cycle regulators such as p16 can induce many factors overlapping with the PASP, but p21 uniquely drives this CXCL14-mediated “timer” mechanism of senescent cell immunosurveillance. —STS
Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G 4 C 2 ) repeat expansion in vitro and in vivo ALS models
Bush, Jessica A. , Aikawa, Haruo , Fuerst, Rita, Li, Yue , Ursu, Andrei , Meyer, Samantha M. , Benhamou, Raphael I. , Chen, Jonathan L. , Khan, Tanya , Wagner-Griffin, Sarah , Meter, Montina J. Van , Tong, Yuquan , Olafson, Hailey, McKee, Kendra , Childs‐Disney, Jessica L. , Zhang, Yong‐Jie , Wang, Eric T. , Wang, Kye Won , Petrucelli, Leonard , Van Meter, Montina J , McKee, Kendra K , Gendron, Tania F , Zhang, Yong-Jie , Coyne, Alyssa N , Wang, Eric T , Wang, Kye Won , Petrucelli, Leonard , Rothstein, Jeffrey D , Disney, Matthew D , Benhamou, Raphael I , Aikawa, Haruo , Gendron, Tania F. , Coyne, Alyssa N. , Yildirim, Ilyas , Rothstein, Jeffrey D. , Disney, Matthew D.

Mayo Clinic

Science Translational Medicine | October 27, 2021 | Volume: 13 | Issue: 617 | Pages: No page available

10.1126/scitranslmed.abd5991 | PMID 34705518 Get It

Small-molecule recruitment of an endogenous nuclease rescues pathologies associated with c9ALS/FTD in vivo by targeting an RNA repeat expansion.
CD36 Identifies a Subpopulation of Adipose-Derived Mesenchymal Stromal Cells with Enhanced Osteogenic Ability.
Camilleri, Emily , Riester, Scott M. , Gustafson, Michael P. , Garces, Catalina Galeano, Paradise, Christopher R. , Glusevic, Martina, Bulur, Peggy A. , Dudakovic, Amel , Dietz, Allan B. , Camilleri, Emily T. , Dietz, Allan B , van Wijnen, Andre J , Camilleri, Emily , Wijnen, André J. van

Mayo Clinic

No container title available | October 25, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-987811/v1 Get It

Abstract Background Adipose-derived mesenchymal stromal cells (AMSCs) represent attractive cellular therapeutics for treatment of various diseases including osteoarthritis and bone degeneration. Preparation and characterization of AMSCs show donor-to-donor variability that indicating that AMSCs are heterogeneous populations of cells. Cell surface markers to identify MSCs, such as CD44, CD90, and CD105, are relatively invariable among AMSCs and do not reflect the heterogeneity of AMSC populations. CD36, a multifunctional surface receptor associated with transport of oxidized low-density lipoproteins and fatty acids, is also expressed by AMSCs but this marker is considerable more variable. Therefore, we assessed whether CD36 can be used to identify subpopulations in AMSCs. Methods Clinical-grade AMSCs were isolated from patient fat biopsies, cultured under xenobiotic-free conditions using human platelet lysate and sorted by flow cytometry or magnetic cell sorting to characterize CD36 expression. CD36 enriched, CD36 depleted, and unsorted AMSCs were characterized using cellular and molecular techniques including proliferation, multilineage potential, RNA-sequencing and bioinformatics, metabolomics, and sensitivity to the CD36 inhibitor sulfosuccinimidyl oleate (SSO). Results CD36 exhibited biphasic expression on AMSCs grown in human platelet lysate. Enrichment of CD36+ AMSCs showed that CD36+ expression identifies a stable subpopulation. Transcriptomic analysis revealed enhancement of calcium transporter genes. Osteogenic differentiation of CD36+ enriched, CD36+ depleted, and unsorted AMSCs showed strikingly enhanced osteogenic calcium deposition and enhanced expression of alkaline phosphatase (ALPL) and osteoprotegrin (TNFRSF11B) in the CD36+ population. While lipid droplets were not altered, adipogenic differentiation showed upregulated gene expression of key adipogenic markers, including fatty acid-binding protein 4 (FABP4) and Adiponectin (ADIPOQ), with CD36+ enrichment. Treatment of CD36+ enriched AMSCs with the SSO showed reduced calcium deposition whereas CD36+ depleted AMSCs were unaffected. Conclusions CD36 exhibits variable expression amongst AMSCs. CD36+ enriched AMSCs are a stable subpopulation with enhanced osteogenic potential that linked to CD36 receptor function. These results may further refine production and clinical application of AMSC cellular therapeutics. Furthermore, the enhanced osteogenic potential of CD36+ AMSCs may be considered for therapeutic regeneration of bone.
S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection
Allegretti, Jessica R. , Kelly, Colleen , Louie, Thomas , Fisher, Monika, Hota, Susy , Misra, Bharat , Hise, Nicholas W. Van, Yen, Eugene F. , Facg, Bullock, Jeff S., Pullman, John, Nathan, Richard, Silverman, Michael , Davis, Ian, Khanna, Sahil , Pardi, Darrell S. , Orenstein, Robert , Grinspan, Ari , El‐Nachef, Najwa , Kraft, Colleen S., Budree, Shrish , Kassam, Zain , Bullock, Jeff S., Davis, Ian, McGill, Sarah , Kraft, Colleen S. , Borody, Thomas Julius

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S64

10.14309/01.ajg.0000773052.38150.f9 Get It

S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection
Allegretti, Jessica R. , Kelly, Colleen , Louie, Thomas , Fisher, Monika, Hota, Susy , Misra, Bharat , Hise, Nicholas W. Van, Yen, Eugene F. , Bullock, Jeff S., Pullman, John, Nathan, Richard, Silverman, Michael , Davis, Ian, Gerardin, Ylaine, Silva, Josh, Khanna, Sahil , Pardi, Darrell S. , Orenstein, Robert , Grinspan, Ari , El‐Nachef, Najwa , Budree, Shrish , Kassam, Zain , Bullock, Jeff S., Davis, Ian, McGill, Sarah , Kraft, Colleen S. , Borody, Thomas Julius

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S63

10.14309/01.ajg.0000773048.24890.7e Get It